149 related items for PubMed ID: 11115437
1. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.
Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM.
Chest; 2000 Dec; 118(6):1538-46. PubMed ID: 11115437
[Abstract] [Full Text] [Related]
2. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
O'Connor B, Bonnaud G, Haahtela T, Luna JM, Querfurt H, Wegener T, Lutsky BN.
Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
[Abstract] [Full Text] [Related]
3. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma.
Sorkness CA, LaForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR.
Clin Ther; 1999 Feb; 21(2):353-67. PubMed ID: 10211538
[Abstract] [Full Text] [Related]
4. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate.
Nathan RA, Nayak AS, Graft DF, Lawrence M, Picone FJ, Ahmed T, Wolfe J, Vanderwalker ML, Nolop KB, Harrison JE.
Ann Allergy Asthma Immunol; 2001 Feb; 86(2):203-10. PubMed ID: 11258691
[Abstract] [Full Text] [Related]
5. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate.
Wardlaw A, Larivee P, Eller J, Cockcroft DW, Ghaly L, Harris AG.
Ann Allergy Asthma Immunol; 2004 Jul; 93(1):49-55. PubMed ID: 15281471
[Abstract] [Full Text] [Related]
6. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler.
Noonan M, Karpel JP, Bensch GW, Ramsdell JW, Webb DR, Nolop KB, Lutsky BN.
Ann Allergy Asthma Immunol; 2001 Jan; 86(1):36-43. PubMed ID: 11206236
[Abstract] [Full Text] [Related]
7. Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis.
Li JT, Goldstein MF, Gross GN, Noonan MJ, Weisberg S, Edwards L, Reed KD, Rogenes PR.
J Allergy Clin Immunol; 1999 Apr; 103(4):622-9. PubMed ID: 10200011
[Abstract] [Full Text] [Related]
8. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis.
Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM.
J Allergy Clin Immunol; 1998 Aug; 102(2):191-7. PubMed ID: 9723660
[Abstract] [Full Text] [Related]
9. A systemic bioactivity comparison of double-strength and regular-strength beclomethasone dipropionate MDI formulations.
Brannan MD, Herron JM, Reidenberg P, Affrime MB.
Ann Allergy Asthma Immunol; 1998 Jan; 80(1):39-44. PubMed ID: 9475565
[Abstract] [Full Text] [Related]
10. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.
Sharpe M, Jarvis B.
Drugs; 2001 Jan; 61(9):1325-50. PubMed ID: 11511026
[Abstract] [Full Text] [Related]
11. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.
Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ.
Am J Respir Crit Care Med; 2004 Nov 01; 170(9):960-6. PubMed ID: 15184207
[Abstract] [Full Text] [Related]
12. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma.
Holgate ST, Arshad H, Stryszak P, Harrison JE.
J Allergy Clin Immunol; 2000 May 01; 105(5):906-11. PubMed ID: 10808170
[Abstract] [Full Text] [Related]
13. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function.
Sheth KK, Cook CK, Philpot EE, Prillaman BA, Witham LA, Faris MA, Klein KC, Rickard KA.
Allergy Asthma Proc; 2004 May 01; 25(2):115-20. PubMed ID: 15176496
[Abstract] [Full Text] [Related]
14. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler.
Bernstein DI, Berkowitz RB, Chervinsky P, Dvorin DJ, Finn AF, Gross GN, Karetzky M, Kemp JP, Laforce C, Lumry W, Mendelson LM, Nelson H, Pearlman D, Rachelefsky G, Ratner P, Repsher L, Segal AT, Selner JC, Settipane GA, Wanderer A, Cuss FM, Nolop KB, Harrison JE.
Respir Med; 1999 Sep 01; 93(9):603-12. PubMed ID: 10542973
[Abstract] [Full Text] [Related]
15. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study.
Aaronson D, Kaiser H, Dockhorn R, Findlay S, Korenblat P, Thorsson L, Källén A.
J Allergy Clin Immunol; 1998 Mar 01; 101(3):312-9. PubMed ID: 9525445
[Abstract] [Full Text] [Related]
16. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.
Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE.
J Allergy Clin Immunol; 2000 Sep 01; 106(3):485-92. PubMed ID: 10984368
[Abstract] [Full Text] [Related]
17. Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial.
Kemp JP, Osur S, Shrewsbury SB, Herje NE, Duke SP, Harding SM, Faulkner K, Crim CC.
Mayo Clin Proc; 2004 Apr 01; 79(4):458-66. PubMed ID: 15065610
[Abstract] [Full Text] [Related]
18. Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma.
Schmier J, Leidy NK, Gower R.
J Asthma; 2003 Jun 01; 40(4):383-93. PubMed ID: 12870834
[Abstract] [Full Text] [Related]
19. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler.
Bousquet J, D'Urzo A, Hebert J, Barraza CH, Boulet LP, Suárez-Chacón R, Harnest U, Lundbäck B, Martinez Morales G, Nieminen MM, Nolop KB, Visser S, Lutsky BN.
Eur Respir J; 2000 Nov 01; 16(5):808-16. PubMed ID: 11153576
[Abstract] [Full Text] [Related]
20. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays.
Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C.
Eur J Clin Pharmacol; 2004 Jun 01; 60(4):265-8. PubMed ID: 15114430
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
